Immix Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Immix Biopharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-25.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 61% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-171.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 56% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Immix Biopharma, Inc. made a loss over the last year. Immix Biopharma, Inc. owes $0.04 for every $1 it owns. Immix Biopharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossImmix Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.02The share price is 3.02 times Immix Biopharma, Inc.'s book value per share, higher than 56% of Healthcare companies in United States.
Market cap
$692 MThe total market value of all of Immix Biopharma, Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$229 MWhat Immix Biopharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.76Net worth divided by the number of shares. The share price of $8.35 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
-34.2%Immix Biopharma, Inc. lost 34.2% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
Owes vs Owns
0.04×Immix Biopharma, Inc. owes $0.04 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Dividend yield
NoneImmix Biopharma, Inc. does not currently pay a dividend.
Profit growth
LossImmix Biopharma, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashImmix Biopharma, Inc. held $99 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Immix Biopharma, Inc.: $692 M ÷ $229 M (30 Jun 2026) = 3.0.
What is Immix Biopharma, Inc.'s return on equity?
Immix Biopharma, Inc. lost 34.2% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
How much does Immix Biopharma, Inc. owe compared with what it owns?
Immix Biopharma, Inc. owes $0.04 for every $1 it owns (low), lower than 97% of Healthcare companies in United States.
Does Immix Biopharma, Inc. pay a dividend?
No. Immix Biopharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.